OKYO Pharma Doses First Patient in OK-101 Phase 2 NCP Trial
Ticker: OKYO · Form: 6-K · Filed: Oct 23, 2024 · CIK: 1849296
Sentiment: bullish
Topics: clinical-trial, drug-development, phase-2
TL;DR
OKYO Pharma just dosed its first patient in a Phase 2 trial for OK-101, a potential NCP treatment. Big step forward!
AI Summary
On October 23, 2024, OKYO Pharma Ltd announced that the first patient has been dosed in its Phase 2 clinical trial for topical ocular OK-101, a treatment for Neuropathic Corneal Pain (NCP). This double-masked, randomized, 12-week placebo-controlled study will evaluate the efficacy and safety of OK-101.
Why It Matters
This milestone marks a significant step in the development of OK-101, potentially offering a new treatment option for patients suffering from the debilitating condition of neuropathic corneal pain.
Risk Assessment
Risk Level: medium — Clinical trial progression carries inherent risks, and the success of Phase 2 is not guaranteed, impacting future development and market potential.
Key Players & Entities
- OKYO Pharma Ltd (company) — Filer of the 6-K report and developer of OK-101
- OK-101 (drug) — Topical ocular treatment being tested
- Neuropathic Corneal Pain (NCP) (medical_condition) — Condition targeted by OK-101
- October 23, 2024 (date) — Date of the announcement and first patient dosing
FAQ
What is the primary objective of the Phase 2 trial for OK-101?
The Phase 2 study is designed to evaluate the efficacy and safety of topical ocular OK-101 in treating Neuropathic Corneal Pain (NCP).
What is the design of the Phase 2 trial?
The trial is double-masked, randomized, and will last for 12 weeks, including a placebo-controlled arm.
What condition is OK-101 intended to treat?
OK-101 is intended to treat Neuropathic Corneal Pain (NCP).
When was the first patient dosed in the Phase 2 trial?
The first patient was dosed on October 23, 2024.
What type of drug is OK-101?
OK-101 is a topical ocular drug.
Filing Stats: 373 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2024-10-23 07:00:28
Filing Documents
- form6-k.htm (6-K) — 24KB
- ex99-1.htm (EX-99.1) — 20KB
- ex99-1_01.jpg (GRAPHIC) — 26KB
- 0001493152-24-042159.txt ( ) — 81KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: October 23, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 Announcement, dated October 23, 2024 4